A groundbreaking study published in the journal Cephalalgia may reshape the future of migraine diagnosis and treatment by identifying biologically distinct migraine subtypes using advanced brain imaging. Migraines affect more than one billion people worldwide and remain one of the leading causes of disability, particularly among young and middle-aged adults. Unlike ordinary headaches, migraines are often accompanied by nausea, vomiting, visual disturbances, and extreme sensitivity to light and sound, significantly impairing quality of life and productivity. Despite their high prevalence, migraine diagnosis and treatment have largely depended on patient-reported symptoms rather than objective biological markers.
In the new study, researchers from Stanford Medicine used functional magnetic resonance imaging (fMRI) to identify two biologically distinct migraine patterns. The study included 111 individuals with migraine and 51 healthy control participants who underwent both structural MRI and functional MRI assessments. By applying advanced computational analysis to the imaging data, investigators discovered that migraine patients could be grouped into two clusters based on differences in brain connectivity and blood flow patterns. One subtype, termed “cluster 1,” showed brain activity patterns relatively similar to healthy individuals and was associated with milder symptoms. In contrast, “cluster 2” demonstrated more pronounced abnormalities involving cortical and subcortical brain networks, suggesting deeper neurological involvement.
Patients classified under cluster 2 were generally older, experienced longer migraine attacks, and reported greater disability and impairment in daily functioning. Interestingly, the frequency of migraine episodes was not significantly different between the two groups, indicating that migraine severity may depend more on underlying brain biology than simply the number of headache days. These findings challenge the current migraine classification system, which mainly categorizes patients into episodic or chronic migraine based on attack frequency. Current guidelines typically reserve preventive therapies for chronic migraine patients experiencing more than 15 headache days per month. The new findings suggest that some patients with episodic migraine may also benefit from early preventive treatment if they belong to a biologically higher-risk subtype.
Researchers believe these discoveries could pave the way for precision medicine in migraine care, enabling clinicians to predict disease progression and tailor therapies according to an individual’s brain biology. The team is now investigating whether blood-based biomarkers and clinical features can reliably identify these imaging-defined subtypes, which would make the approach more practical and accessible in routine healthcare settings. Since fMRI remains expensive and not universally available, identifying simpler clinical or laboratory markers could help translate these findings into everyday migraine management. Experts believe the study represents an important step toward objective, biology-based diagnosis and more personalized treatment strategies for millions of people living with migraine worldwide.
References
- Jaiashre Sridhar, Babaei M, Sanjanwala BM, Cowan RP, DeSouza DD. Neuroimaging-based subtyping of migraine identifies clinically distinct phenotypes. Cephalalgia. 2026 Mar 1;46(3):03331024261433982.